Fractures
Stem cell therapy with fracturesFrom:MiamiFootSurgeryViews:14 0ratingsTime:00:57More inHowto Style

Read more here:
Fractures - Video

HIV and AIDS Cure With Stem Cells Now Accepted Stem Cell Therapy
youtu.be Whether as differentiated or undifferentiated, whether from sheep stem cells or from rabbit; delivered frozen or fresh, today #39;s stem cell therapies are showing real promise and helping HIV-AIDS sufferers around the world, today! Cautious not to claim they can cure ANYTHING, today #39;s ethical clinics offer hope for AIDS-HIV sufferers worldwide, although the one Thai clinic licensed by the German stem cell technique is in Bangkok. For information to help you make an informed, personal decision, check out StemCell-Asia.info today.From:Kerry DeanViews:7 0ratingsTime:01:03More inPeople Blogs

Here is the original post:
HIV and AIDS Cure With Stem Cells Now Accepted Stem Cell Therapy - Video

Stem Cell Therapy for osteoarthritis Cosmetic Surgery Thailand Review - Urban Beauty Thailand
Plastic Surgery Thailand Cost Reviews Adipose-derived stemcell fat graft + PRP + Fat transfer for natural augmentation on all part of body such as Face, Breast, Butt, Hand etc. Adistem is originally and can deliver Stemcell for cell survial more than 300millions cell.Compare with other methods such as CAL, Adistem is most Cell Survival among others result is permanantly. Normally, the cost is around 350000baht/appx $11667usd but we can offer as $9000usd/appx 270000THB all inclusive with 5 nights facilities. Urban Beauty Thailand is a bespoke One-Stop Travel and Beauty Solution. Arranging the best medical tourism package for you, from your flights, to whichever Cosmetic Surgery, Beauty Treatments or Dental Treatments are right for you, at the right treatment center, whether in Bangkok, Phuket, Koh Samui, or Pattaya. We also arrange excursions and holiday activities during your stay. Cosmetic surgery Thailand, Plastic surgery Thailand cost reviews. Provide FREE Consultation olivia@urbanbeautythailand.com http://www.urbanbeautythailand.comFrom:UrbanBeautyThaiViews:15 1ratingsTime:07:21More inTravel Events

The rest is here:
Stem Cell Therapy for osteoarthritis Cosmetic Surgery Thailand Review - Urban Beauty Thailand - Video

FAQ-3 of 19 -How Do Stem Cells Work in Stem Cell Therapy?
youtu.be Short video describing how stem cells home in on their injured organs, find their place and then differentiate into the cells that the hurt or diseased or dysfunctional organ NEEDS. For more on this and how stem cells MIGHT help you or your loved one, go to StemCell-Asia.info now.From:Karridine1Views:3 0ratingsTime:01:06More inScience Technology

View post:
FAQ-3 of 19 -How Do Stem Cells Work in Stem Cell Therapy? - Video

FAQ-3 of 19: How Do Stem Cells Actually Work in Stem Cell Therapy?
youtu.be An informative, brief video describing how stem cells home in on their injured organs, find their places and then differentiate into the cells that the hurt or diseased or dysfunctional organ NEEDS to heal itself. For more on this and how stem cells MIGHT help you or your loved one, go to StemCell-Asia.info now.From:John PepperViews:0 0ratingsTime:01:06More inNonprofits Activism

See the original post:
FAQ-3 of 19: How Do Stem Cells Actually Work in Stem Cell Therapy? - Video

stem cells | Cryo-Cell - Cord Blood Banking Information For Parents
http://www.cordbloodrecommendation.com You never know when you might need this blood and it might give your child a new life. Why Bank Cord Blood?Cell therapy has become a more ideal method to treat certain diseases than bone morrow transplants. Most of the private and public banks were founded during the 1990s. In a laboratory test, cord blood stem cells were transplanted into rodents with controlled strokes. With the success from transfusions creating immune system stability, and creating new oxygen baring cells for many diseases, researchers are hoping that more diseases can not only be treated effectively, but possibly stopped in their tracks altogether. In cancer patients, such as those with leukemia, the introduction of HSC #39;s into the body may rapidly produce healthy cells that can replace destroyed cells from chemotherapy and/or hopefully prevent infections that often create complications or even death, during the treatment process. If you pass all the tests you will be free to donate your baby #39;s blood. Although some will allow you to prepay during your pregnancy so as to not have to pay the amount all in one lump sum, but in general all initial fees must be paid well in advance of delivery in order to utilize the private storage services. According to the most current data, the prospect of needing a stem cell transplant in any individuals Life is 1 in 217! So you can imagine that the likelihood of your baby, or one of your family members needing this kind of help is ...From:kristinagraddyViews:0 0ratingsTime:01:31More inTravel Events

See the original post:
stem cells | Cryo-Cell - Cord Blood Banking Information For Parents - Video

RGO Walking
T-6 Asia A Complete Injury. March 4 2011 is the date of my injury. I have had 2 stem cell treatments at Cell Medicine Institute, Panama City, Panama.From:TheBncfilmsViews:857 2ratingsTime:02:41More inEntertainment

View post:
RGO Walking - Video

Audio Book Review: The Stem Cell Hope: How Stem Cell Medicine Can Change Our Lives by Alice Park ...
http://www.AudioBookMix.com This is the summary of The Stem Cell Hope How Stem Cell Medicine Can Change Our Lives by Alice Park (Author), Walter Dixon (Narrator).From:BookReviewsChanViews:3 0ratingsTime:01:27More inEntertainment

Continue reading here:
Audio Book Review: The Stem Cell Hope: How Stem Cell Medicine Can Change Our Lives by Alice Park ... - Video

FAQ-6 of 19: How Soon Do I Get Help From Stem Cells in Stem Cell Therapy?
youtu.be When you choose stem cell therapy as your treatment, and your board-certified doctor okays you for stem cell therapy, how soon can you expect effects? There #39;s no one-answer-fits-all, but this short video gets across the gist of stem cell therapy. For more personalized information or more FAQ on stem cell therapy at the only licensed clinic in Thailand, visit StemCell-Asia.infoFrom:Harvey WallbangerViews:0 0ratingsTime:01:26More inScience Technology

See the original post:
FAQ-6 of 19: How Soon Do I Get Help From Stem Cells in Stem Cell Therapy? - Video

NEW YORK, Nov. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases)

http://www.reportlinker.com/p01022392/Autologous-Stem-Cell-and-Non-Stem-Cell-Based-Therapies-Market-2012-2017-Neurodegenerative-cardiovascular-cancer--autoimmune-skin-and-infectious-diseases.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Autologous cell therapies are new therapeutic intervention where it introduces or uses cells or tissues from the individual, cultured, expanded and re-introduced at the site of the disease of the donor. They are widely promoted as next pillar or advancement in medical care.

Growth of the market is very rapid especially in regulatory approvals, applications areas and rapid improvements in efficacy of treatment; it has enormous advantages over allogenic stem cell therapies. Autologous transplants are relatively safe procedures, with less rates of complications and infections compared with allogenic transplants. In many instances, much of the procedure can be done on an outpatient basis. It helps in treating various dreadful diseases by transplanting their own body cells where it results in meager chances of transplant rejection.

We have also profiled leading players of this industry with their recent developments and other strategic industry activities. These include: Neostem (U.S.), Tengion (U.S.), Brainstorm Cell Therapeutics (U.S.), Dendreon Corporation (U.S.), Georgia Health Sciences University (U.S.), Regenexx (U.S.), Regeneus (Australia), Cytori Therapeutics (U.S.), Tigenix (Belgium).

Scope of the Report

This research report titled "Autologous Cell Therapy (2012-2017)" provides details about various ACT based treatments and their application areas. Every health regulatory bodies will be expecting companies and universities to develop therapy treatments, which are safer, affordable, robust, rapid, easy to use, effective and deliverable to the end user. ACT treatments for particular application areas it is safe, experiencing robust growth, minimal steps of procedure to follow and rapid in deriving the results. As for now the treatments prices are not affordable, but by the intrusion of government bodies, it will definitely experience a immense market growth.

The report gives a detailed analysis about state of the art of autologous cell therapies. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally. It also consists of funding details of the innovative therapy and recent activities in terms of mergers & acquisitions of the company, revenue forecasting. It includes latest therapy details and products which are available for licensing and approvals from various regulatory bodies. Using drivers, restraints and challenges it is forecasted for a period of five years i.e. 2012-2017. Opportunity strategy evaluation has been included which gives information for investors.

Autologous Cell Therapy technology is changing the medicinal treatments by introducing various new therapies. Its scope is vast and promising for the future despite challenges.

Read more here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer ...

ScienceDaily (Oct. 19, 2012) Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted a two-year clinical trial comparing two-year survival probabilities for patients transplanted with peripheral blood stem cells or bone marrow stem cells from unrelated donors. The goal was to determine whether graft source, peripheral blood stem cells or bone marrow, affects outcomes in unrelated donor transplants for patients with leukemia or other hematologic malignancies.

Fifty transplant centers in the United States and Canada participated in this phase III study, which randomized 278 patients to receive bone marrow and 273 patients to receive peripheral blood stem cells as the graft source for transplant. The results of the study are in the Oct. 18 issue of The New England Journal of Medicine.

According to the trial analyses, there were no observed differences in overall survival, relapse, non-relapse mortality, or acute graft-versus-host disease (GHVD) between the patients receiving peripheral blood stem cells or bone marrow stem cells from unrelated donors. GVHD is a serious and often deadly post-transplant complication that occurs when the newly transplanted donor cells attack the transplant recipient's body. While engraftment was faster in patients receiving peripheral blood stem cells, there was a higher incidence of overall chronic GVHD in these patients (53 percent) than in those transplanted with bone marrow stem cells (40 percent). Patients receiving transplants of peripheral blood stem cells from unrelated donors also had a higher incidence of chronic GVHD affecting multiple organs (46 percent) than patients who received bone marrow stem cells (31 percent).

"Although peripheral blood stem cells from related donors have demonstrated clinical benefits, our trial demonstrates that when these stem cells originate from unrelated donors, they are not superior to bone marrow stem cells in terms of patient survival, and they increase the risk for chronic GVHD," said Anasetti, lead study author. "More effective strategies to prevent GVHD are needed to improve outcomes for all patients receiving unrelated donor transplants."

Peripheral blood stem cells are stem cells originally found in the bone marrow that have been moved into the blood stream by a special regimen of drugs. Unlike bone marrow stem cells, which must be extracted from the bones in an operating room, peripheral blood stem cells are more easily obtained through apheresis, a process similar to regular blood donation, which collects the peripheral blood stem cells through a tube inserted in a vein. A critical step before the transplant involves finding a donor that is tissue matched to the recipient.

About one-third of patients who need a peripheral blood stem cell or bone marrow transplant for treatment of leukemia or another blood disease are able to secure a related donor. According to the National Marrow Donor Program, for the 70 percent who cannot find a donor within their family, most will be able to find an unrelated donor. Because the majority of transplant patients need cells from unrelated donors, it's necessary to better understand the risks associated with transplants of unrelated donor cells.

Clinical trials on related donor transplants have demonstrated that peripheral blood stem cell transplants in patients with leukemia and other blood diseases result in better engraftment, lower relapse rates, and increased survival compared with transplants with bone marrow stem cells. However, those trials also found that peripheral blood stem cell transplants carry an increased risk of GVHD. Patients who survive early post-transplant may develop chronic GVHD, a disabling condition managed with long-term immunosuppressant therapy.

Many transplant centers are increasingly using peripheral blood stem cells as a source for adult stem cells because of their superiority in clinical trials that have directly compared outcomes between peripheral blood stem cells and bone marrow stem cells from related donors. However, there has not been a comparative study of the two transplant sources that has prospectively analyzed patient outcomes in unrelated donor transplants.

The study was funded by the National Heart, Lung and Blood Institute (U10HL069294), the National Cancer Institute and the National Marrow Donor Program.

Share this story on Facebook, Twitter, and Google:

Read more:
No survival advantage with peripheral blood stem cells versus bone marrow, study suggests

The nuclei of brain stem cells in some Parkinson's patients become misshapen with age. The discovery opens up new ways to target the disease.

Nubby nucleus: Brain cells from a deceased Parkinsons patient have deformed nuclei (right) compared with normal brain cells from an individual of a similar age. Merce Marti and Juan Carlos Izpisua Belmonte

Stem cells in the brains of some Parkinson's patients are increasingly damaged as they age, an effect that eventually diminishes their ability to replicate and differentiate into mature cell types. Researchers studied neural stem cells created from patients' own skin cells to identify the defects. The findings offer a new focus for therapeutics that target the cellular change.

The report, published today in Nature, takes advantage of the ability to model diseases in cell culture by turning patient's own cells first into so-called induced pluripotent stem cells and then into disease-relevant cell typesin this case, neural stem cells. The basis of these techniques was recognized with a Nobel Prize in medicine last week.

The authors studied cells taken from patients with a heritable form of Parkinson's that stems from mutations in a gene. After growing several generation of neural stem cells derived from patients with that mutation, they saw the cell nuclei start to develop abnormal shapes. Those abnormalities compromise the survival of the neural stem cells, says study coauthor Ignacio Sancho-Martinez of the Salk Institute for Biological Studies in La Jolla, California.

Today's study "brings to light a new avenue for trying to figure out the mechanism of Parkinson's," says Scott Noggle of the New York Stem Cell Foundation. It also provides a new set of therapeutic targets: "Drugs that target or modify the activity [of the gene] could be applicable to Parkinson's patients. This gives you a handle on what to start designing drug screens around."

The strange nuclei were also seen in patients who did not have a known genetic basis for Parkinson's disease. The authors suggest this indicates that dysfunctional neural stem cells could contribute to Parkinson's. While that conclusion is "highly speculative," says Ole Isacson, a neuroscientist at Harvard Medical School, the study demonstrates the "wealth of data and information that we now can gain from iPS cells."

See original here:
Parkinson's cells

Washington, October 13 (ANI): In a new study, researchers have taken the first steps to create neural-like stem cells from muscle tissue in animals.

"Reversing brain degeneration and trauma lesions will depend on cell therapy, but we can't harvest neural stem cells from the brain or spinal cord without harming the donor," Osvaldo Delbono, lead author of the study from Wake Forest Baptist Medical Center, said.

"Skeletal muscle tissue, which makes up 50 percent of the body, is easily accessible and biopsies of muscle are relatively harmless to the donor, so we think it may be an alternative source of neural-like cells that potentially could be used to treat brain or spinal cord injury, neurodegenerative disorders, brain tumours and other diseases, although more studies are needed," Delbono said.

In an earlier study, the Wake Forest Baptist team isolated neural precursor cells derived from skeletal muscle of adult transgenic mice.

In the current research, the team isolated neural precursor cells from in vitro adult skeletal muscle of various species including non-human primates and aging mice, and showed that these cells not only survived in the brain, but also migrated to the area of the brain where neural stem cells originate.

Another issue the researchers investigated was whether these neural-like cells would form tumours, a characteristic of many types of stem cells. To test this, the team injected the cells below the skin and in the brains of mice, and after one month, no tumours were found.

"Right now, patients with glioblastomas or other brain tumours have very poor outcomes and relatively few treatment options," Alexander Birbrair, first author of the study, said.

"Because our cells survived and migrated in the brain, we may be able to use them as drug-delivery vehicles in the future, not only for brain tumours but also for other central nervous system diseases," he added.

The findings of the study have been published online in the journals Experimental Cell Research and Stem Cell Research. ANI)

See the rest here:
Stem cells from muscle tissue 'may help cure neurodegenerative diseases'

Friday, Oct. 12, 2012

Harvard University said neither it nor Massachusetts General Hospital have ever authorized any iPS-related clinical studies by Hisashi Moriguchi, who claims to have achieved the first clinical application using the revolutionary stem cell technology.

"No clinical trials related to Moriguchi's work have been approved by institutional review boards at either Harvard University or Massachusetts General Hospital," a statement issued by Harvard and related institutes said Thursday.

The statement confirmed that Moriguchi "was a visiting fellow at Massachusetts General Hospital from 1999-2000," but added that he "has not been associated with (the institution) or Harvard since that time."

Moriguchi, a researcher at University of Tokyo Hospital, claimed to be a visiting lecturer at Harvard and to have conducted clinical trials at Massachusetts General Hospital with other researchers to transplant artificial cardiac muscle cells developed from iPS cells into six patients with heart disease.

The claim came just after Shinya Yamanaka of Kyoto University and a British scholar were jointly awarded this year's Nobel Prize in physiology or medicine for their research on iPS cells. Yamanaka and John Gurdon were credited with the discovery that mature human cells can be reprogrammed as immature cells capable of developing into all types of body parts.

"Research has been conducted after going through due procedures, such as consultations with a university ethics committee," Moriguchi claimed. "I have been told my method of creating iPS cells is different from the one used by Yamanaka (and Gurdon), but I have been doing it my way and no problems have been identified after transplants."

Moriguchi, who is thought to have asked a heart surgeon to carry out cell transplants, unveiled details about the treatment at a meeting of annual stem-cell research conference at Rockefeller University in New York held Wednesday and Thursday.

But the event's organizer, the nonprofit New York Stem Cell Foundation, subsequently said it "has received information from Harvard University that raises legitimate questions concerning a poster presentation" by Moriguchi, and has withdrawn it from the conference.

Moriguchi graduated from Tokyo Medical and Dental University with a degree in nursing science and does not have a license to practice medicine, according to a professor who taught him as an undergraduate.

View original post here:
Doubt cast on clinical stem cell tests

Regenevda recently opened its brand new flagship facility in Beverly Hills, specializing in cutting edge anti-aging treatments such as Stem Cell Therapy.

Beverly Hills, CA (PRWEB) October 12, 2012

Dr. Thom Lobe is an internationally respected surgeon and has been in practice for over 30 years. Consistently pioneering advances in medicine, Dr. Lobe was one of the first doctors to ever separate conjoined twins. Consistently working to help make advances in medicine, Dr. Lobe also has over 200 publications to his credit.

Overseeing the business aspect of Regenevda is Lindsey Combs. She is responsible for sales, staff, accounting, facility management, and business development. A graduate of the University of California, Los Angeles, Ms. Combs has been working in the anti-aging field for over 10 years and has been a California Licensed Esthetician since 2003.

Being one of the very few physicians in the country to hold the most advanced board certification (FAARM), Dr. Lobe is able to offer Stem Cell Therapy at the Regenevda clinic. Inside each persons own body, there are special cells in nearly every organ and tissue that have the ability to help heal damage. These special cells are called Stem Cells and this therapy works by harvesting these cells from a persons own blood, bone marrow, or fat and can help with different conditions. Some examples of procedures that use Stem Cell Therapy are: Stem Cell Facelifts, Stem Cell Breast Augmentation, and Stem Cell Joint Therapy. Stem Cell treatments are safe, non-invasive, and are done under local anesthesia.

Intravenous Nutrition Therapy (or IV Vitamin Therapy) is another anti-aging and rejuvenation treatment that can also help patients prevent migraines, lose weight, fight chronic infections like hepatitis, candida, lyme disease, as well as fight acute infections like the flu and mono. IV Therapy works by using intravenous solutions to deliver vitamins and minerals directly to the body cells. This bypasses the digestive system and provides a more direct method of delivery, which ensures that all of the nutrients required are delivered, allowing the patient to feel an improvement in condition almost immediately.

Human Growth Hormone (HGH) Therapy is another advanced treatment offered at Regenevda. HGH is secreted by the Pituitary gland and fuels cell growth and reproduction. This production peaks at adolescence. Over time, due to the effect of aging, the production of HGH slows down dramatically. As production declines, it makes it more difficult for the body to recover from physical and mental exertion. HGH Therapy acts as a supplement for HGH deficient adults to lessen body fat, boost lipid lineament, improve memory, promote bone density, as well as decrease risk factors that involve cardio-vascular conditions. If used at the onset of the decrease in HGH production, HGH Therapy can help curtail early aging and even be used as preventive measure against osteoporosis. A complete analysis of the patients sex hormones, evaluation of glucose regulation and functions of the adrenal gland, thyroid gland, and pancreas are performed before the treatment is administered for optimal results.

Combining decades of medical experience with the most cutting edge advances in medical technology, the Regenevda clinic looks to pave the way for the future of anti-aging treatments. The Regenevda Beverly Hills Institute of Cellular Therapy is located at 50 North La Cienega Boulevard. For any inquiries, they can be reached at 855-734-3638, or visit http://www.regeneveda.com.

About Regenevda :

Regeneveda, home of The Beverly Hills Institute of Cellular Therapy, provides state-of-the-art Stem Cell Therapy. Stem Cell Therapy is an effective treatment for chronic conditions such as Arthritis, Diabetes, Chronic Sports Injuries, and Chronic Pain, but is also revolutionizing anti-aging treatments such as Breast Enhancement, Erectile Dysfunction, and Facial Aging.

Visit link:
Regenevéda Opens Flagship Stem Cell Therapy Clinic in Beverly Hills

Friday, Oct. 12, 2012

NEW YORK A team of researchers has transplanted artificial cardiac muscle cells developed from multipurpose stem cells into six patients in the United States in the world's first clinical application of iPS cells, one of the researchers said Wednesday.

Shinya Yamanaka, who won this year's Nobel Prize in medicine or physiology for his development of iPS cells, declined comment on the transplants, while other experts said details about the medical performance should be carefully evaluated.

The researchers developed the muscle cells from induced pluripotent stem cells produced from the patients' livers and transplanted them to the patients, said Hisashi Moriguchi, a visiting professor at Harvard University.

A 34-year-old American male patient who was the first to receive the transplant in February now has normal heart functions and has been discharged from the hospital, Moriguchi said.

The patient suffered from liver cancer and received a liver transplant in February 2009. He developed ischemic cardiomyopathy this February, prompting the researchers to conduct the heart surgery.

The researchers took cells from the patient's original liver, which was kept after removal for the 2009 transplant, and developed iPS cells by adding protein and other medical agents from which they produced cardiac muscle cells. The muscle cells were placed in 30 locations in the patient's heart.

No rejection or cancer development was found in the heart, and his heart function gradually recovered to normal levels 10 days after the surgery, they said.

"We need to improve the efficacy and safety of such medical treatment . . . and think of ways to reduce economic burden on patients," Moriguchi said.

The researchers used an improved technique to produce iPS cells developed by Yamanaka, the professor from Kyoto University who jointly won this year's Nobel with John Gurdon of Britain. Such cells have the potential to grow into any type of body tissue.

Read more:
U.S. marks first iPS clinical applications

STOCKHOLM (Reuters) - A British and a Japanese scientist won the Nobel Prize for Medicine on Monday for work on creating stem cells, opening the door to new methods to diagnose and treat diseases.

Briton John Gurdon and Japan's Shinya Yamanaka equally share the prize of 8 million crowns ($1.2 million), the Nobel Assembly at Sweden's Karolinska Institute said in a statement.

"These groundbreaking discoveries have completely changed our view of the development and specialization of cells."

The discovery offered a new way to create stem cells with the ability to become different types of tissue by effectively turning back the clock on adult cells, restoring them to a so-called "pluripotent" state.

The practical result can be that skin cells can be obtained from ill people to find out more about their diseases and develop new therapies.

Medicine is the first of the Nobel prizes awarded each year. Prizes for achievements in science, literature and peace were first awarded in 1901 in accordance with the will of dynamite inventor and businessman Alfred Nobel. ($1 = 6.5846 Swedish crowns)

(Editing by Patrick Lannin, Alistair Scrutton and Mark Heinrich)

See the original post here:
Japanese, UK scientists win Nobel medicine prize for work with stem cells

Kyoto University Professor Shinya Yamanaka talks with Japan's Prime Minister Yoshihiko Nada by a mobile phone during a news conference in Kyoto, western Japan, in this photo taken by Kyodo October 8, 2012.

By Tan Ee Lyn Reuters Wednesday, Oct 10, 2012

HONG KONG - The Internet is full of advertisements touting stem cell cures for just about any disease -- from diabetes, multiple sclerosis, arthritis, eye problems, Alzheimer's and Parkinson's to spinal cord injuries -- in countries such as China, Mexico, India, Turkey and Russia.

Yamanaka, who shared the Nobel Prize for Medicine on Monday with John Gurdon of the Gurdon Institute in Cambridge, Britain, called for caution.

"This type of practice is an enormous problem, it is a threat. Many so-called stem cell therapies are being conducted without any data using animals, preclinical safety checks," said Yamanaka of Kyoto University in Japan.

"Patients should understand that if there are no preclinical data in the efficiency and safety of the procedure that he or she is undergoing ... it could be very dangerous," he told Reuters in a telephone interview.

Yamanaka and Gurdon shared the Nobel Prize for the discovery that adult cells can be transformed back into embryo-like stem cells that may one day regrow tissue in damaged brains, hearts or other organs.

"I hope patients and lay people can understand there are two kinds of stem cell therapies. One is what we are trying to establish. It is solely based on scientific data. We have been conducting preclinical work, experiments with animals, like rats and monkeys," Yamanaka said.

"Only when we confirm the safety and effectiveness of stem cell therapies with animals will we initiate clinical trials using a small number of patients."

Yamanaka, who calls the master stem cells he created "induced pluripotent stem cells" (iPS), hopes to see the first clinical trials soon.

Read more here:
Nobel laureate Yamanaka warns of rogue "stemcell therapies"

STOCKHOLM (Reuters) - Scientists from Britain and Japan shared a Nobel Prize on Monday for the discovery that adult cells can be transformed back into embryo-like stem cells that may one day regrow tissue in damaged brains, hearts or other organs.

John Gurdon, 79, of the Gurdon Institute in Cambridge, Britain and Shinya Yamanaka, 50, of Kyoto University in Japan, discovered ways to create tissue that would act like embryonic cells, without the need to collect the cells from embryos.

They share the $1.2 million Nobel Prize for Medicine, for work Gurdon began 50 years ago and Yamanaka capped with a 2006 experiment that transformed the field of "regenerative medicine" - the search for ways to cure disease by growing healthy tissue.

"These groundbreaking discoveries have completely changed our view of the development and specialisation of cells," the Nobel Assembly at Stockholm's Karolinska Institute said.

All of the body starts as stem cells, before developing into tissue like skin, blood, nerves, muscle and bone. The big hope is that stem cells can grow to replace damaged tissue in cases from spinal cord injuries to Parkinson's disease.

Scientists once thought it was impossible to turn adult tissue back into stem cells. That meant new stem cells could only be created by taking them from embryos, which raised ethical objections that led to research bans in some countries.

As far back as 1962 Gurdon became the first scientist to clone an animal, making a healthy tadpole from the egg of a frog with DNA from another tadpole's intestinal cell. That showed that developed cells carry the information to make every cell in the body - decades before other scientists made world headlines by cloning the first mammal from adult DNA, Dolly the sheep.

More than 40 years later, Yamanaka produced mouse stem cells from adult mouse skin cells by inserting a small number of genes. His breakthrough effectively showed that the development that takes place in adult tissue could be reversed, turning adult tissue back into cells that behave like embryos.

Stem cells created from adult tissue are known as "induced pluripotency stem cells", or iPS cells. Because patients may one day be treated with stem cells from their own tissue, their bodies might be less likely to reject them.

"The eventual aim is to provide replacement cells of all kinds," Gurdon's institute explains on its website.

Read the original post:
UK, Japan scientists win Nobel for adult stem cell discovery

The 2012 Nobel Prize for medicine has been awarded to stem cell researchers John Gurdon and Shinya Yamanaka of Britain and Japan. They take the first Nobel prize of the year, with a flurry to follow over the next week.

Judges in Stockholm said on Monday that the medicine prize had been awarded to the researchers "for the discovery that mature cells can be reprogrammed to become pluripotent," saying that this discovery had "revolutionized our understanding of how cells and organisms develop."

Gurdon and Yamanaka are stem cell researchers who are seeking ways to obtain embryonic stem cells - a kind of genetic blank slate, cells that can be 'programmed' to take on many different forms and perform different functions - from the cells of an adult. Embryos themselves are another more controversial source of stem cells.

"We are trying to find ways of obtaining embryo cells from the cells of an adult," Gurdon writes on his Gurdon Institute website. "The eventual aim is to provide replacement cells of all kinds starting from usually obtainable cells of an adult individual."

The British scientist also said such a system was advantageous because the stem cells could be obtained from the patient themselves, reducing the risk of rejection when they were employed as a treatment.

The medals will be doled out in December, the winners named in the next few days

Stem cells appear to have potential to treat a wide range of illnesses, with a major barrier to the research the ethical implications of obtaining the cells from unborn foetuses.

A busy week in the Swedish capital

This year's laureates in the field of physics will be named on Tuesday, with chemistry following on Wednesday and perhaps the most famous Nobel Peace Prize to be awarded on Friday. As is tradition, there is no set date for the Nobel Prize for Literature - but that will almost certainly fill the gap in the schedule on Thursday. The economics prize winner or winners will be named on October 15.

All the prizes will be awarded in Stockholm simultaneously at a December 10 ceremony.

Read the original:
Stem cell pioneers win Nobel medicine honors